FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

APPROVAL

OMB Number:	3235-0287
Estimated average bure	den
hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	de pursuant to a or written plan for the equity securities of the ed to satisfy the conditions of Rule			
1. Name and Address  GTCR INVES	of Reporting Person* TMENT XI LLC	2	2. Issuer Name and Ticker or Trading Symbol  MARAVAI LIFESCIENCES HOLDINGS,  INC. [ MRVI ]	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner Officer (give title Other (specify)
(Last) C/O GTCR, LLC	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/28/2024	below) below)
300 N. LASALLE	SUITE 5600		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person
(Street)				X Form filed by More than One Reporting Person
CHICAGO	IL	60654		
(City)	(State)	(Zip)		

# Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (li 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		d Of (D) (Instr. 3, 4 and 5)  Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Class B common stock	05/28/2024		<b>D</b> <sup>(1)</sup>		8,409,946	D	(1)	110,684,080(2)	I	See footnotes(3)(4)(7)(8)
Class A common stock	05/28/2024		C <sup>(1)</sup>		8,409,946	A	(1)	30,090,979	I	See footnotes <sup>(7)(8)</sup>
Class A common stock	05/28/2024		S		9,940,974(5)	D	\$9.815	20,150,005(6)	I	See footnotes <sup>(7)(8)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		Securities I Derivative S	rities Underlying E rative Security S		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5) Securities Beneficially Owned Following Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Common Units	(1)	05/28/2024		C			8,409,946	(1)	(1)	Class A common stock	8,409,946	(1)	110,684,080	I	See footnotes <sup>(1)(4)(7)(8)</sup>	

1. Name and Address	s of Reporting Person *		
GTCR INVE	STMENT XI LL	<u>C</u>	
(Last)	(First)	(Middle)	
C/O GTCR, LLC			
300 N. LASALL	E SUITE 5600		
(Street)			
CHICAGO	IL	60654	
(City)	(State)	(Zip)	

	<b></b>	
(Last)	(First)	(Middle)
	JIFESCIENCES HO GE CIRCLE SUIT	
TOTTO WATERID	GE CIRCLE SUIT	
Street)		
SAN DIEGO	CA	92121
(City)	(State)	(Zip)
	of Reporting Person*	HOLDINGS 2, LLC
		, , , , , , , , , , , , , , , , , , ,
(Last)	(First)	(Middle)
C/O MARAVAI I	LIFESCIENCES HO	OLDINGS, INC.
10770 WATERID	GE CIRCLE SUIT	E 200
Street)		
SAN DIEGO	CA	92121
(City)	(State)	(Zip)
	of Reporting Person *	
GTCR FUND	XI/B LP	
(Loot)	(Eirot)	/B#: 441~ \
(Last) C/O GTCR, LLC	(First)	(Middle)
300 N. LASALLE	SUITE 5600	
Street)		60654
CHICAGO	IL	60654
(City)	(State)	(Zip)
1. Name and Address	of Reporting Person*  XI/C LP	
(Last)	(First)	(Middle)
C/O GTCR, LLC 300 N. LASALLE	SHITE 5600	
OVU IN, LASALLE	, SOTTE 3000	
Street)		
CHICAGO	IL	60654
(City)	(State)	(Zip)
		\ <b>←</b> i₽ <i>)</i>
1. Name and Address GTCR CO-INV	of Reporting Person*	
GICK CO-III	V LUI AILF	
(Last)	(First)	(Middle)
the state of the s	. <i>,</i>	
C/O GTCR, LLC		
	SUITE 5600	
	SUITE 5600	
300 N. LASALLE		
300 N. LASALLE	IL	60654
C/O GTCR, LLC 300 N. LASALLE Street) CHICAGO (City)		60654 (Zip)

1. Name and Address	s of Reporting Person *		
	NERS XI/A&C	LP	
(Last)	(First)	(Middle)	
C/O GTCR, LLC			
300 N. LASALL	E SUITE 5600		
(Street)			
CHICAGO	IL	60654	
(City)	(State)	(Zip)	
1. Name and Address	s of Reporting Person *		
GTCR PART	NERS XI/B LP		
(Last)	(First)	(Middle)	
C/O GTCR, LLC			
300 N. LASALL	E SUITE 5600		
(Street)			
CHICAGO	IL	60654	
(City)	(State)	(Zip)	

#### **Explanation of Responses:**

- 1. Pursuant to the Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. (the "Issuer"), Maravai Topco Holdings, LLC ("Topco LLC") and Maravai Life Sciences Holdings, LLC ("MLSH 1") (the "Exchange Agreement"), the units in Topco LLC (the "Common Units") (together with an equal number of shares of Class B common stock, par value \$0.01 per share, of the Issuer (the "Class B common stock")) are exchangeable for shares of Class A common stock, par value \$0.01 per share, of the Issuer (the "Class A common stock") on a one-for-one basis. The Common Units do not expire.
- 2. Represents 110,684,080 shares of Class B common stock held directly by MLSH 1.
- 3. Shares of Class B common stock confer no economic rights on the holders thereof. Except as provided in the Issuer's Amended and Restated Certificate of Incorporation or as otherwise required by applicable law, holders of Class B common stock will be entitled to one vote per share on all matters to be voted on by holders of the Issuer's Class A common stock. Upon exchange of Common Units that are held by MLSH 1 and reported in Table II hereof, an equal number of shares of Class B common stock will be delivered to the Issuer and cancelled for no consideration.
- 4. Represents Class B common stock and Common Units held directly by MLSH 1 after giving effect to the exchange of 8,409,946 Common Units (and cancellation of an equal number of shares of Class B common stock) for 8,409,946 shares of Class A common stock.
- 5. Represents (i) 8,409,946 shares of Class A common stock sold by MLSH 1 and (ii) 1,531,028 shares of Class A common stock sold by Maravai Life Sciences Holdings 2, LLC ("MLSH 2").
- 6. Represents 20,150,005 shares of Class A common stock held directly by MLSH 2.
- 7. MLSH 1 and MLSH 2 are each managed by a board of managers. GTCR Fund XI/C LP ("GTCR Fund XI/C") controls the board of managers of MLSH 2. GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI") control the board of managers of MLSH 1. GTCR Partners XI/A&C LP ("GTCR Partners XI/A&C") is the general partner of GTCR Fund XI/C. GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of GTCR Co-Invest XI, GTCR Partners XI/A&C and GTCR Partners XI/B. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Aaron D. Cohen, Sean L. Cunningham, David A. Donnini, Constantine S. Mihas and Collin E. Roche, and no single person has voting or dispositive authority over the Class A common stock or Class B common stock held of record by MLSH 1 and MLSH 2.
- 8. Each of GTCR Partners XI/A&C, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class A common stock held of record by MLSH 2. Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the shares of Class B common stock held of record by MLSH 1 and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the shares held of record by MLSH 1 and MLSH 2 except to the extent of his pecuniary interest therein.

### Remarks

Each of the reporting persons is a director-by-deputization solely for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

/s/ Kevin Herde, as chief financial officer of Maravai Life Sciences 05/30/2024 Holdings, LLC /s/ Kevin Herde, as chief financial 05/30/2024 officer of Maravai Life Sciences Holdings 2, LLC /s/ Jeffrey Wright, by power of attorney for GTCR Fund XI/B LP 05/30/2024 /s/ Jeffrey Wright, by power of 05/30/2024 attorney for GTCR Fund XI/C LP /s/ Jeffrey Wright, by power of 05/30/2024 attorney for GTCR Co-Invest XI LP /s/ Jeffrey Wright, by power of attorney for GTCR Partners 05/30/2024 XI/A&C LP /s/ Jeffrey Wright, by power of attorney for GTCR Partners XI/B 05/30/2024 LP /s/ Jeffrey Wright, by power of attorney for GTCR Investment XI 05/30/2024

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).